Introduction: Hyperphosphatemia is one of the major factors associated with the
development of vascular calcification in patients with chronic kidney disease (CKD). Since …

Introduction Among the clinical and metabolic complications of progressive chronic kidney
disease (CKD), CKD-mineral bone disorder (CKD-MBD) significantly contributes to morbidity …

All-cause mortality and cardiovascular-related mortality have both been linked to abnormal
serum phosphate concentrations in chronic kidney disease (CKD). Aberrant serum …

Introduction: Hyperphosphatemia in chronic kidney disease (CKD) is considered as an
independent risk factor for surrogate clinical end points like vascular calcification (VC) and …

Convincing epidemiological data have repeatedly shown that increased phosphate levels
as well as generous phosphate intakes are associated with unfavourable outcome both in …

Rising levels of serum phosphate occur late in the course of chronic kidney disease (CKD)
and have been easy targets for nephrologists to treat using phosphate binding drugs, as …

BACKGROUND: Phosphate binders are widely used to control serum phosphorus levels in
patients with chronic kidney disease (CKD). We analyzed the effects of phosphate binders …

Adequate phosphate management in end-stage CKD remains a mainstay of our therapeutic
approaches in this population, and additional promising drugs are in development and may …

Hyperphosphatemia is a characteristic feature of chronic kidney disease-mineral and bone
disorder (CKD-MBD). Phosphorus excess is an independent risk factor for cardiovascular …

Hyperphosphatemia is a late complication of chronic kidney disease (CKD). It is a major non-
traditional cardiovascular risk factor in CKD. The management of hyperphosphatemia is …